We report the ability of a gene expression signature to predict response to neoadjuvant chemotherapy in early breast cancer, and also describe transcriptomic changes during treatment Overall design: T
"Source of Patients Patients entered into this study were from the NSABP B-40 trial in which patients were randomized to one of three chemotherapy regimens with one-half of the patients also randomize
